Intralesional macular atrophy in antiVEGF therapy for age-related macular degeneration in the IVAN trial

Harding, SP ORCID: 0000-0003-4676-1158, Bailey, Clare, Scott, Lauren, Rogers, Chris, Reeves, Barnaby, Hamill, Barbra, Peto, Tunde and Chakravarthy, Usha
(2018) Intralesional macular atrophy in antiVEGF therapy for age-related macular degeneration in the IVAN trial. Ophthalmology, 126 (1). 75 - 86.

Access the full-text of this item by clicking on the Open Access link.
[img] Text
BaileyEtAl_Ophthalmology2018.docx - Author Accepted Manuscript

Download (24MB)


Purpose To report on the development and progression of macular atrophy (MA) and its relationship with morphologic and functional measures in study and fellow eyes in the Inhibition of vascular endothelial growth factor (VEGF) in Age-related Choroidal Neovascularisation trial. Design Reading center analysis of data from a randomized controlled trial. Participants Participants with previously untreated neovascular age-related macular degeneration (nAMD) in the study eye. Methods Color, fluorescein angiography (FA) and OCT images acquired at baseline and during the 2-year follow-up were graded systematically for presence of MA. Regression models were constructed to explore relationships between MA and lesion morphology and vision measures (best-corrected distance and near acuity, reading speed and index, contrast sensitivity). Main Outcome Measures Primary outcome was development of intralesional MA (≥175 μm greatest linear dimension of choroidal vessels seen on FA and/or color, aided by OCT) lying within the maximum footprint of the neovascular lesion. Results Study eye data were available for 594 of 610 participants; 57 (9.6%) showed intralesional MA at baseline. Incident intralesional MA occurred in 24.4% by the final visit and extralesional MA in only 1.54%. In fellow eyes, an established nAMD lesion was present at baseline in 248 of whom 42 (16.9%) showed intralesional MA at baseline and 32 (12.9%) developed incident intralesional MA. The odds of incident intralesional MA by final visit were lower in study eyes that had ≥50% classic CNV at baseline (odds ratio [OR], 0.39; 95% confidence interval [CI], 0.19–0.80; P = 0.010), subretinal fluid at final visit (OR, 0.41; 95% CI, 0.25–0.76; P = 0.004), or pigment epithelial detachment at final visit (OR, 0.40; 95% CI, 0.21–0.74; P = 0.004). Secondary analyses of incident or progressed intralesional MA in study eyes supported these findings, with odds increasing if the fellow eye had baseline intralesional MA (OR, 2.43; 95% CI, 1.09–5.44; P = 0.030). No significant associations were observed between development of intralesional MA and any other morphologic or visual function measure. Conclusions Macular atrophy frequently develops within an nAMD lesion in eyes receiving anti–VEGF therapy over 2 years. No associations between incident MA and drug or treatment frequency or visual function were detected, providing some reassurance to clinicians; however, the longer-term effects remain unknown.

Item Type: Article
Depositing User: Symplectic Admin
Date Deposited: 28 Aug 2018 06:11
Last Modified: 06 Oct 2022 05:56
DOI: 10.1016/j.ophtha.2018.07.013
Open Access URL:
Related URLs: